Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | Director | November 11, 2019 | November 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date November 11, 2019 · Filed November 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,384 |
Last balance in matching sequence
After 2019-11-11 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2019-11-11 · Exercise / conversion · Acquired 6,573 · Balance 54,957 F1: This number includes unvested restricted stock units previously reported. Row 2 · 2019-11-11 · Exercise / conversion · Acquired 10,353 · Balance 65,310 F1: This number includes unvested restricted stock units previously reported. Row 3 · 2019-11-11 · Sale · Disposed 16,926 · Balance 48,384 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.97 to $118.83, inclusive. the reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. F1: This number includes unvested restricted stock units previously reported. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.45 · Expires 2020-07-24 | Direct | 0 |
Reported balance
After 2019-11-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-11 · Exercise / conversion · Disposed 6,573 · Balance 0 F3: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 · Expires 2021-07-23 | Direct | 0 |
Reported balance
After 2019-11-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-11 · Exercise / conversion · Disposed 10,353 · Balance 0 F3: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This number includes unvested restricted stock units previously reported.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.97 to $118.83, inclusive. the reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
F3: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2019 Filed Nov 13, 2019 22:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,353 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001127602-19-032642 · form4.xml · derivative · entry 5 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,353 shares Expires 2021-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,573 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001127602-19-032642 · form4.xml · derivative · entry 4 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,573 shares Expires 2020-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 16,926 | $118.26 | $2,001,668.76 |
DisclosureSEC source: 0001127602-19-032642 · form4.xml · nonDerivative · entry 3 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,384 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.97 to $118.83, inclusive. the reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 10,353 | $35.50 | $367,552.21 |
DisclosureSEC source: 0001127602-19-032642 · form4.xml · nonDerivative · entry 2 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 6,573 | $45.45 | $298,742.85 |
DisclosureSEC source: 0001127602-19-032642 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,696 | $134.15 | $227,518.40 |
DisclosureSEC source: 0001127602-19-026407 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,384 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.08 to $134.15, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:33 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025267 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,080 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: Balance reflects the reporting person's transfer of 4,442 shares of the Issuer's common stock to his former spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his former spouse. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-19-006806 · form4.xml · derivative · entry 3 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 8,196 | $86.52 | $709,117.92 |
DisclosureSEC source: 0001127602-19-006806 · form4.xml · nonDerivative · entry 2 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,062 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-19-006806 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 21:56 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 4,329 | $103.02 | $445,973.58 |
DisclosureSEC source: 0001127602-18-036606 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,062 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.96 to $103.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024057 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,391 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,678 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · derivative · entry 23 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,678 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,440 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · derivative · entry 22 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,678 Underlying: Common Stock · 5,440 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,678 | $34.41 | $57,731.59 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 21 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $56.80 | $17,040.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 20 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,017 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $56.78 | $11,356.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 19 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,317 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $56.77 | $17,031.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 18 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,517 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $56.74 | $17,020.50 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 17 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,817 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 400 | $56.73 | $22,692.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 16 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,117 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $56.72 | $5,672.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 15 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,517 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $56.71 | $5,671.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 14 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,617 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,200 | $56.70 | $68,040.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 13 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,717 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 400 | $56.69 | $22,676.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 12 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,917 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $56.68 | $17,004.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 11 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,317 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $56.67 | $17,001.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 10 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,617 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $56.67 | $5,666.50 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 9 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,917 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $56.66 | $5,666.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 8 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,017 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 400 | $56.65 | $22,660.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 7 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,117 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $56.63 | $11,326.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 6 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,517 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 240 | $56.62 | $13,588.80 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 5 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,717 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $56.60 | $11,320.00 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 4 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,957 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 235 | $56.58 | $13,296.30 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 3 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,157 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 65 | $56.57 | $3,677.05 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 2 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,392 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 5,440 | $34.41 | $187,163.20 |
DisclosureSEC source: 0001127602-17-032602 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 22:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,329 | $39.27 | $169,999.83 |
DisclosureSEC source: 0001127602-17-024401 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,017 F1 · shares: Restricted Stock Unit grant which vests 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| March 24, 2017 Filed Apr 27, 2017 21:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,580 | $0.00 Strike: $27.24 | $0.00 |
DisclosureSEC source: 0001127602-17-015752 · form4.xml · derivative · entry 3 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,580 shares Expires 2017-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| March 24, 2017 Filed Apr 27, 2017 21:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 8,580 | $40.00 | $343,200.00 |
DisclosureSEC source: 0001127602-17-015752 · form4.xml · nonDerivative · entry 2 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,688 F1 · shares: Cashless exercise and sale of net shares pursuant to a 10b5-1 trading plan. Read SEC document |
| March 24, 2017 Filed Apr 27, 2017 21:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 8,580 | $27.24 | $233,719.20 |
DisclosureSEC source: 0001127602-17-015752 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 5,683 | $40.30 | $229,024.90 |
DisclosureSEC source: 0001127602-16-070019 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,688 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.